Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment

Award Number: R44CA174037
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2014
PERIOD OF PERFORMANCE END DATE: 01/31/2019

Group Awards By:

View Award Description

Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment - ¿ DESCRIPTION (provided by applicant): Numerous regulatory proteins are tightly controlled by ubiquitin conjugation and deconjugation and deviations from this dynamic process are manifested in clinical disorders such as cancer, inflammation, neurodegenerative disorders, and metabolic diseases. The deubiquitylase (DUB) USP7 plays multiple regulatory roles, all of which are pro-survival/antiapoptotic. One of its most intriguing roles is the furtherance of immune-evasion, whereby tumors employ various mechanisms to escape detection and killing by the host defense (T-and NK-cell mediated) immune system. Abrogation of tumor tolerance induction has become a leading anticancer strategy, as it should in principle work on a broad spectrum of cancers. Clinical activity of antibodies to two receptors that trigger suppression of T-cell defens (CTLA4 and PD-1) has led to USFDA approval of three biologicals for treating melanoma. While the strategy is valid, opportunities for improvement of the therapeutic index exist in the areas of mechanism (multiple mechanisms can lead to tolerance, suggesting that combination therapies will be needed for maximum efficacy) and treatment cost (a serious issue especially with biologicals). The involvement of USP7 in sustaining immune evasion immediately suggests a therapeutic strategy - inhibitors of USP7 destabilize the transcription factor Foxp3, which is needed to activate a population of Tcells (Tregs) that limit activation of tumoricidal T effector (Teff) cells. Thus a USP7 inhibitor should break Treg-induced tolerance allowing Teff cells to kill the tumor. In Phase I, Progenra's selective USP7 inhibitor P5091 was confirmed to diminish Foxp3 stability and eliminate Treg cells' ability to induce tolerance by down-regulating Teff cells as predicted. Moreover, P05091 mediated anti-tumor activity in the AE17 mesothelioma syngeneic tumor model only in immunocompetent mice, thus suppressing tumor growth in this model by inhibiting T cell anergy and not by direct cytotoxic effects of the kind observed in other models. Also in Phase I, the potency and drug-like properties of P05091 were improved by the generation of a series of compounds with EC50 ~100-200nM while maintaining selectivity and efficacy in cellular and in vivo proof of concept models. In Phase II, lead optimization will focus on further improvement of pharmacological properties; PK, toxicology, and efficacy studies will guide chemical synthesis. The goal is to identify potent and selective compounds with efficacy against lung cancer and other tumor models with the ultimate commercial goal of initiating clinical development.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2017	PROGENRA, INC	277 GREAT VALLEY PKWY	MALVERN	PA	19355	CHESTER	USA	Cancer Treatment Research	000	3	7/8/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $748,944 )
2017	2017	PROGENRA, INC	277 GREAT VALLEY PKWY	MALVERN	PA	19355	CHESTER	USA	Cancer Treatment Research	000	3	1/26/2017	NON-COMPETING CONTINUATION	$748,944
														Subtotal = $748,944

Issue Date FY: 2016 ( Subtotal = $748,944 )
2016	2016	PROGENRA INC	271 GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Cancer Treatment Research	000	2	2/2/2016	COMPETING CONTINUATION	$748,944
														Subtotal = $748,944

Grand Total All Awards = $1,497,888

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment

Award Number: R44CA174037

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2014

PERIOD OF PERFORMANCE END DATE: 01/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer